TABLE 5.
Treatment regimens for donor-derived WNV infection in transplant recipientsa
| No. improved/No. treated | |
|---|---|
| Encephalitis (N=14 patients) | |
| Supportive care | 5/7 |
| IV immunoglobulin alone | 1/3 |
| IV immunoglobulin, fresh frozen immune plasma | 1/1 |
| IV immunoglobulin, fresh frozen immune plasma, interferon | 1/1 |
| IV immunoglobulin, interferon | 0/2 |
| WNV fever (N=1 patient) | |
| Supportive care | 1/1 |
| Asymptomatic (N=5 patients) | |
| IV immunoglobulin alone | 2/2 |
| IV immunoglobulin, fresh frozen immune plasma | 1/1 |
| IV immunoglobulin, ribavirin | 1/1 |
| Supportive care | 1/1 |
a
IV immunoglobulin (polyvalent=6, Omr-IgG-am with high titer WNV antibodies=5).
Fresh frozen immune plasma with WNV IgG antibodies.
Interferon (interferon alfa-2b, subcutaneous).
WNV, West Nile virus.